Zevra Therapeutics Inc
ZVRA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$610.47M
Close$
$-10.42
193.3% downside
Current Fair Value
193.3% downsideOvervalued by 193.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $610.47 Million |
|---|---|
| Enterprise Value | $485.99 Million |
| Earnings per Share | $1.4 |
| Beta | 0.98 |
| Outstanding Shares | 59,155,970 |
Return
| Return on Equity | 26.37% |
|---|---|
| Return on Assets | 18.96% |
| Return on Invested Capital | 30.86% |
Valuation & Multiples
| P/E Ratio | 10.7 |
|---|---|
| PEG | -12.13 |
| Price to Sales | 5.59 |
| Price to Book Ratio | 3.72 |
| Enterprise Value to Revenue | 3.57 |
| Enterprise Value to EBIT | 6.2 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$0.14
Consensus analyst estimateRevenue Estimate
$37.08 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 8, 2027
EPS Estimate
$0.16
Consensus analyst estimateRevenue Estimate
$40.09 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 199.53% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.49%▼ 70.57% |
|---|---|
| Total Invested | $42.13M▼ 93.46% |
| Investors Holding | 37▼ 131.00% |
About Zevra Therapeutics Inc
24 employees
CEO: Travis Mickle
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...